Russell Green, director product growth for Drug Discovery and Synthetic Biology, Automata, describes three reasons why automation should become an integral part of the vaccine development process.
As vaccine development continues to advance and innovative techniques such as mRNA sequencing are being successfully used to deliver results, scientists must focus on fast-tracking progress, reducing the risk of errors and ensuring vaccines are accessible to as many people as possible.